SlideShare a Scribd company logo
Presenting by:
MR. PURUSHOTHAM K N
Asst. Professor
Department of
Pharmaceutical Chemistry
SACCP,B.G.Nagara
2021-2022
Stereochemistry and Drug
Action
• Stereochemistry mainly deals
with the spatial arrangements
of the atoms or group of
atoms in a molecules.
• A clear understanding of stereochemistry is
crucial for the study of complex molecules
that are biologically important e.g. Protiens,
carbohydrates, nucleic acids and drug
molecules (especially in relation to their
behavior and pharmacological actions).
IMPORTANT DEFINITIONS
• Isomerism refers to the phenomenon in
which more than one compounds have the
same chemical formula but different
chemical structures. And those chemical
compounds that have identical chemical
formulae but they differ in physical or
chemical properties and the arrangement of
atoms in the molecule are called isomers.
Therefore, the compounds that possess
isomerism are called “isomers”.
• Chirality is defined as an object or a compound which is
asymmetric and cannot be superimposed over its mirror
image (for example, our both palms) is known as ‘chiral’ or
‘stereocenter’ and this property is known as “chirality”. The
chirality is due to the three-dimensional or spatial
arrangements of the molecules and a carbon is said to be
chiral carbon when it is bonded with four different
substituents to it. The asymmetry of the molecule or
chirality is mainly responsible for the optical activity in
such organic compounds.
• Example: Asymmetric or chiral compounds
•A carbon within an organic
compound that contains four
different atoms or group of
atoms (substituents) bonded to it.
•A carbon with double and triple
bond cannot be considered as
asymmetric because it contain 2
and 3 total bonds respectively.
• STEREOISOMERS: Isomers that have same
molecular formula and connectivity but differ
in a way that atoms are oriented in space – i.e;
Difference between isomers lies only in 3D
arrangements of atoms.
• ENANTIOMER:
Greek word: enantio : opposite merons : parts
Stereoisomers with non superimposable
mirror images.
• DIASTEREOMER : Diastereomers are
stereoisomers that are not mirror images of
one another and are non-superimposable on
one another. Stereoisomers with two or more
stereocenters can be diastereomers.
Stereoisomers
Configurational isomer :
• Geometric isomers : (a) cis & trans system
/ E & Z system
• Relative configuration / Fischer projection (
L & D configuration)
• Absolute configuration (R & S
configuration
CIS AND TRANS CONFIGURATION
L AND D CONFIGURATION
R and S CONFIGURATION
• Priority of an atom is
determined by its atomic
number
• Order of substituents going
from highest to lowest
priority.
• Clockwise – R (rectus).
• Anticlockwise – S (sinister).
• Unless established
experimentally no idea
whether (+) or (-) rotation is
associated with R or S
configuration
Importance of the chirality in drugs
• This stereoisomerism results in different physical and
chemical properties of the compound. If this
compound happens to be drug then it results in
different pharmacokinetic and pharmaco dynamic
properties
• The importance of chiral drugs in the drug
development space cannot be understated. In
pharmaceutical industries, 56% of the drugs currently
in use are chiral molecules and 88% of the last ones are
marketed as racemates (or racemic mixtures),
consisting of an equimolar mixture of two enantiomers
Thalidomide-disastrous
• biological activity of the wrong
enantiomer
• In 1960 in Europe, racemic
thalidomide was given to
pregnant females to cure
morning sickness.
• This led to deformations in
babies and neurotoxic effects.
• These were due to S-
thalidomide.
• R-thalidomide contained the
desired therapeutic activity
EXAMPLES OF CHIRAL DRUGS
• INTRAVENOUS ANAESTHETICS
• LOCAL ANAESTHETICS
• INHALATIONAL AGENTS
• NUEROMUSCULAR BLOCKING AGENTS
• SOME OTHER DRUGS
Intravenous anaesthetics
Etomidate
• Administered as a single isomer: R-isomer.
• Site of action: GABAA receptor.
• R-isomer is 15 times more potent than the S-isomer.
• S-isomer lacks hypnotic activity.
LOCAL ANAESTEHTICS
BUPIVACAINE
• Long acting local anaesthetic marketed as 50:50
racemic mixture. Reports of death due to
• Bupivacaine induced CNS toxicity and cardiotoxicity on
accidental intravenous injection and difficult
resuscitation following cardiotoxicity. Safer alternatives
• Levobupivacaine
• Ropivacaine These are S- enantiomers of bupivacaine.
• Ropivacaine is the first ‘pure’ enantiomer containing
>99% of the S-form
• Potential advantages of single enantiomer
products:
• Less complex, more selective
pharmacodynamic profile
• Potential for an improved therapeutic index
• Less complex pharmacokinetic profile
Reduced potential for complex drug
interactions
• Less complex relationship between plasma
concentration and effect
Biological Discrimination
Pharmacokinetics stereoselectivity
Absorption
• Passive intestinal absorption
• Carrier transporter stereoselectivity
Distribution
• Protein binding
• Tissue distribution
Metabolism
• first pass metabolism
• Phase I and phase II metabolism
Elimination
Absorption and stereoselectivity
• Passive intestinal absorption For the majority of
racemic drugs, absorption appears to be by
passive diffusion , provided no stereoselectivity
Carrier mediated transporter
• Stereo selective
intestinal transporter
is the main cause for
marked differences in
the oral absorption of
enantiomers. L-
Methotrexate have 40
fold higher Cmax and
AUC than D-
Methotrexate
Distribution
Protein binding
• Stereo selective plasma protein binding could
influence distribution and elimination because
the major determinant of drug distribution and
elimination is protein binding.
• The enantiomers may display different
magnitudes of stereoselectivity between the
various proteins found in plasma
• Ex// the R- propranolol binding to albumin is
greater than S- propranolol and the opposite is
observed for 1 -acid glycoprotein.
R- propranolol
• Highly albumin bound
• Less potent
S- propranolol
• highly bound to AAG
available as unbound
• 40-100 time more
potent
• Metabolism first pass metabolism Stereo
selective drug metabolism is commonly
observed in vitro for racemic drugs and can
results in substantial differences in the vivo
plasma concentration - time profiles between
enantiomers due to stereo selective
bioavailability or drug disposition.
• some time the two isomers compete with
each other to bind the enzyme binding site,
this result in inhibition the metabolism of the
one enantiomer. Ex// propaphenone
REFERENCES
1. https://www.slideshare.net/AZMINMOGAL/stereoch
emistry-83184901?qid=6fc35486-
740a45b083bdf812d3804882&v=&b=&from_search=
3
2. https://www.slideshare.net/arzoodharasandiya/case
-study-of-stereochemistry-and-drug-
design85443779?qid=6fc35486-740a-45b0-
83bdf812d3804882&v=&b=&from_search=2
3. https://www.slideshare.net/rudramadhab1/chiraldru
g?qid=37d78d5f-a23d-4f72-8268-
08b3b65105f7&v=&b=&from_search=7
STEREOCHEMISTRY.pptx

More Related Content

What's hot

Realization that stereo selectivity is a pre-requisite for evolution.pptx
Realization that stereo selectivity is a pre-requisite for evolution.pptxRealization that stereo selectivity is a pre-requisite for evolution.pptx
Realization that stereo selectivity is a pre-requisite for evolution.pptx
ParthaGhosh498013
 
.Case study and enantioselectivity in drug ADME.pptx
.Case study and enantioselectivity in drug ADME.pptx.Case study and enantioselectivity in drug ADME.pptx
.Case study and enantioselectivity in drug ADME.pptx
PurushothamKN1
 
Traube purine synthesis
Traube purine synthesisTraube purine synthesis
Traube purine synthesis
Karanvir Rajput
 
STEREOCHEMISTRY AND DRUG ACTION.pptx
STEREOCHEMISTRY AND DRUG ACTION.pptxSTEREOCHEMISTRY AND DRUG ACTION.pptx
STEREOCHEMISTRY AND DRUG ACTION.pptx
AchalYawalkar
 
Enantio selectivity in pharmacokinetics
Enantio selectivity in pharmacokineticsEnantio selectivity in pharmacokinetics
Enantio selectivity in pharmacokinetics
ROHIT PAL
 
organic reaction
organic reactionorganic reaction
organic reaction
NiketBajare
 
Suzuki and Shapiro reaction
Suzuki and Shapiro reaction Suzuki and Shapiro reaction
Suzuki and Shapiro reaction
Shalinee Chandra
 
Peptidomimitics
PeptidomimiticsPeptidomimitics
Peptidomimitics
Mahendra G S
 
Reactions of heterocyclic chemistry
 Reactions of heterocyclic chemistry Reactions of heterocyclic chemistry
Reactions of heterocyclic chemistry
suraj wanjari
 
Synthetic Reagents & Applications in Organic Chemistry
Synthetic Reagents & Applications in Organic ChemistrySynthetic Reagents & Applications in Organic Chemistry
Synthetic Reagents & Applications in Organic Chemistry
Ajay Kumar
 
Validation & Diversity of drug targets
Validation & Diversity of drug targetsValidation & Diversity of drug targets
Validation & Diversity of drug targets
SnigdhaBharadwaaj
 
Analog design medicinal chemistry
Analog design medicinal chemistryAnalog design medicinal chemistry
Analog design medicinal chemistry
Mohit umare
 
Combating drug resistance in anticancer therapy
Combating drug resistance in anticancer therapy Combating drug resistance in anticancer therapy
Combating drug resistance in anticancer therapy
ManingcinaSephe
 
ANALOG DESIGN.pdf
ANALOG DESIGN.pdfANALOG DESIGN.pdf
ANALOG DESIGN.pdf
ShivalingMP
 
Protecting groups
Protecting groupsProtecting groups
Protecting groups
aqsaakram15
 
named reaction.pptx
named reaction.pptxnamed reaction.pptx
named reaction.pptx
DhanashreeKavhale
 
Biological drug targets.pptx
Biological drug targets.pptxBiological drug targets.pptx
Biological drug targets.pptx
PurushothamKN1
 
TRAUBE PURINE SYNTHESIS.pptx
TRAUBE PURINE SYNTHESIS.pptxTRAUBE PURINE SYNTHESIS.pptx
TRAUBE PURINE SYNTHESIS.pptx
PratikKapse8
 
Global and local restrictions Peptidomimetics
Global and local restrictions Peptidomimetics Global and local restrictions Peptidomimetics
Global and local restrictions Peptidomimetics
ASHOK GAUTAM
 

What's hot (20)

Realization that stereo selectivity is a pre-requisite for evolution.pptx
Realization that stereo selectivity is a pre-requisite for evolution.pptxRealization that stereo selectivity is a pre-requisite for evolution.pptx
Realization that stereo selectivity is a pre-requisite for evolution.pptx
 
.Case study and enantioselectivity in drug ADME.pptx
.Case study and enantioselectivity in drug ADME.pptx.Case study and enantioselectivity in drug ADME.pptx
.Case study and enantioselectivity in drug ADME.pptx
 
Traube purine synthesis
Traube purine synthesisTraube purine synthesis
Traube purine synthesis
 
STEREOCHEMISTRY AND DRUG ACTION.pptx
STEREOCHEMISTRY AND DRUG ACTION.pptxSTEREOCHEMISTRY AND DRUG ACTION.pptx
STEREOCHEMISTRY AND DRUG ACTION.pptx
 
Enantio selectivity in pharmacokinetics
Enantio selectivity in pharmacokineticsEnantio selectivity in pharmacokinetics
Enantio selectivity in pharmacokinetics
 
organic reaction
organic reactionorganic reaction
organic reaction
 
Suzuki and Shapiro reaction
Suzuki and Shapiro reaction Suzuki and Shapiro reaction
Suzuki and Shapiro reaction
 
Peptidomimitics
PeptidomimiticsPeptidomimitics
Peptidomimitics
 
Reactions of heterocyclic chemistry
 Reactions of heterocyclic chemistry Reactions of heterocyclic chemistry
Reactions of heterocyclic chemistry
 
Synthetic Reagents & Applications in Organic Chemistry
Synthetic Reagents & Applications in Organic ChemistrySynthetic Reagents & Applications in Organic Chemistry
Synthetic Reagents & Applications in Organic Chemistry
 
Validation & Diversity of drug targets
Validation & Diversity of drug targetsValidation & Diversity of drug targets
Validation & Diversity of drug targets
 
Analog design medicinal chemistry
Analog design medicinal chemistryAnalog design medicinal chemistry
Analog design medicinal chemistry
 
Mitsunobu reaction
Mitsunobu reactionMitsunobu reaction
Mitsunobu reaction
 
Combating drug resistance in anticancer therapy
Combating drug resistance in anticancer therapy Combating drug resistance in anticancer therapy
Combating drug resistance in anticancer therapy
 
ANALOG DESIGN.pdf
ANALOG DESIGN.pdfANALOG DESIGN.pdf
ANALOG DESIGN.pdf
 
Protecting groups
Protecting groupsProtecting groups
Protecting groups
 
named reaction.pptx
named reaction.pptxnamed reaction.pptx
named reaction.pptx
 
Biological drug targets.pptx
Biological drug targets.pptxBiological drug targets.pptx
Biological drug targets.pptx
 
TRAUBE PURINE SYNTHESIS.pptx
TRAUBE PURINE SYNTHESIS.pptxTRAUBE PURINE SYNTHESIS.pptx
TRAUBE PURINE SYNTHESIS.pptx
 
Global and local restrictions Peptidomimetics
Global and local restrictions Peptidomimetics Global and local restrictions Peptidomimetics
Global and local restrictions Peptidomimetics
 

Similar to STEREOCHEMISTRY.pptx

Stereochemistry
StereochemistryStereochemistry
Stereochemistry
AZMIN MOGAL
 
Clinical pharmacokinetics and pharmacodynamics of stereo isomeric drugs
Clinical pharmacokinetics and pharmacodynamics of stereo isomeric drugsClinical pharmacokinetics and pharmacodynamics of stereo isomeric drugs
Clinical pharmacokinetics and pharmacodynamics of stereo isomeric drugs
Sazan Jamil Ali
 
chiral pharmacokinetic
chiral pharmacokineticchiral pharmacokinetic
chiral pharmacokinetic
maryam kazemi
 
Chiral drug
Chiral drugChiral drug
Chiral drug
Rudra madhab
 
medicinal chemistry .pptx
medicinal chemistry .pptxmedicinal chemistry .pptx
medicinal chemistry .pptx
Justalazydudewithgla
 
stereoisomersautosaved-190208040126.pptx
stereoisomersautosaved-190208040126.pptxstereoisomersautosaved-190208040126.pptx
stereoisomersautosaved-190208040126.pptx
Noorelhuda2
 
Stereoisomers in pharmacology
Stereoisomers in pharmacologyStereoisomers in pharmacology
Stereoisomers in pharmacology
chandiniyrao
 
Stereochemistry
StereochemistryStereochemistry
Stereochemistry
Muhammad Rashad
 
group-01-stereochemistry-210827075815 (1).pptx
group-01-stereochemistry-210827075815 (1).pptxgroup-01-stereochemistry-210827075815 (1).pptx
group-01-stereochemistry-210827075815 (1).pptx
Noorelhuda2
 
Stereochemistry
StereochemistryStereochemistry
Stereochemistry
IstiukMahmudTaimur
 
some concepts of stereochemistry
some concepts of stereochemistrysome concepts of stereochemistry
some concepts of stereochemistry
ManishaPanwar13
 
5. STRUCTURE BASED DD.pptx
5. STRUCTURE BASED DD.pptx5. STRUCTURE BASED DD.pptx
5. STRUCTURE BASED DD.pptx
ABDULRAUF411
 
isomers
isomersisomers
isomers
som allul
 
Des.term paper
Des.term paperDes.term paper
Des.term paper
dessyofosu
 
Principles and Applications of Structure Activity Relationship
Principles and Applications of Structure Activity RelationshipPrinciples and Applications of Structure Activity Relationship
Principles and Applications of Structure Activity Relationship
Nizam Ashraf
 
Regulatory requirements-Chiral drugs.pptx
Regulatory requirements-Chiral drugs.pptxRegulatory requirements-Chiral drugs.pptx
Regulatory requirements-Chiral drugs.pptx
Kishore Kumar Hotha., PhD
 
Overview and determination of enantiomeric impurities
Overview and determination of enantiomeric impuritiesOverview and determination of enantiomeric impurities
Overview and determination of enantiomeric impurities
Veeprho Laboratories
 
Drug receptor interactions
Drug receptor interactionsDrug receptor interactions
Drug receptor interactions
Saurabh Negi
 

Similar to STEREOCHEMISTRY.pptx (20)

Stereochemistry
StereochemistryStereochemistry
Stereochemistry
 
Clinical pharmacokinetics and pharmacodynamics of stereo isomeric drugs
Clinical pharmacokinetics and pharmacodynamics of stereo isomeric drugsClinical pharmacokinetics and pharmacodynamics of stereo isomeric drugs
Clinical pharmacokinetics and pharmacodynamics of stereo isomeric drugs
 
chiral pharmacokinetic
chiral pharmacokineticchiral pharmacokinetic
chiral pharmacokinetic
 
Chiral drugs
Chiral drugsChiral drugs
Chiral drugs
 
Chiral drug
Chiral drugChiral drug
Chiral drug
 
medicinal chemistry .pptx
medicinal chemistry .pptxmedicinal chemistry .pptx
medicinal chemistry .pptx
 
stereoisomersautosaved-190208040126.pptx
stereoisomersautosaved-190208040126.pptxstereoisomersautosaved-190208040126.pptx
stereoisomersautosaved-190208040126.pptx
 
Stereoisomers in pharmacology
Stereoisomers in pharmacologyStereoisomers in pharmacology
Stereoisomers in pharmacology
 
Stereochemistry
StereochemistryStereochemistry
Stereochemistry
 
group-01-stereochemistry-210827075815 (1).pptx
group-01-stereochemistry-210827075815 (1).pptxgroup-01-stereochemistry-210827075815 (1).pptx
group-01-stereochemistry-210827075815 (1).pptx
 
Stereochemistry
StereochemistryStereochemistry
Stereochemistry
 
some concepts of stereochemistry
some concepts of stereochemistrysome concepts of stereochemistry
some concepts of stereochemistry
 
5. STRUCTURE BASED DD.pptx
5. STRUCTURE BASED DD.pptx5. STRUCTURE BASED DD.pptx
5. STRUCTURE BASED DD.pptx
 
isomers
isomersisomers
isomers
 
Des.term paper
Des.term paperDes.term paper
Des.term paper
 
Principles and Applications of Structure Activity Relationship
Principles and Applications of Structure Activity RelationshipPrinciples and Applications of Structure Activity Relationship
Principles and Applications of Structure Activity Relationship
 
Peiper 1
Peiper 1Peiper 1
Peiper 1
 
Regulatory requirements-Chiral drugs.pptx
Regulatory requirements-Chiral drugs.pptxRegulatory requirements-Chiral drugs.pptx
Regulatory requirements-Chiral drugs.pptx
 
Overview and determination of enantiomeric impurities
Overview and determination of enantiomeric impuritiesOverview and determination of enantiomeric impurities
Overview and determination of enantiomeric impurities
 
Drug receptor interactions
Drug receptor interactionsDrug receptor interactions
Drug receptor interactions
 

More from PurushothamKN1

Chemistry of Prostaglandins,Leukotrienes and Thromboxanes.pptx
Chemistry of Prostaglandins,Leukotrienes and Thromboxanes.pptxChemistry of Prostaglandins,Leukotrienes and Thromboxanes.pptx
Chemistry of Prostaglandins,Leukotrienes and Thromboxanes.pptx
PurushothamKN1
 
SAR of Quinolines.pptx
SAR of Quinolines.pptxSAR of Quinolines.pptx
SAR of Quinolines.pptx
PurushothamKN1
 
OECD GUIDELINES.pptx
OECD GUIDELINES.pptxOECD GUIDELINES.pptx
OECD GUIDELINES.pptx
PurushothamKN1
 
modify of peptidomimetics.pptx
modify of peptidomimetics.pptxmodify of peptidomimetics.pptx
modify of peptidomimetics.pptx
PurushothamKN1
 
INDUSTRIAL SAFETY.pptx
INDUSTRIAL SAFETY.pptxINDUSTRIAL SAFETY.pptx
INDUSTRIAL SAFETY.pptx
PurushothamKN1
 
01. Combating Drug Resistance.pptx
01. Combating Drug Resistance.pptx01. Combating Drug Resistance.pptx
01. Combating Drug Resistance.pptx
PurushothamKN1
 
02.Anticonvulsant and H1 and H2 receptor antagonist.pptx
02.Anticonvulsant and H1 and H2 receptor antagonist.pptx02.Anticonvulsant and H1 and H2 receptor antagonist.pptx
02.Anticonvulsant and H1 and H2 receptor antagonist.pptx
PurushothamKN1
 
02.High through output screening.pptx
02.High through output screening.pptx02.High through output screening.pptx
02.High through output screening.pptx
PurushothamKN1
 
Adrenergic and cholinergic agents pptx.pptx
Adrenergic and cholinergic agents pptx.pptxAdrenergic and cholinergic agents pptx.pptx
Adrenergic and cholinergic agents pptx.pptx
PurushothamKN1
 
analog design.pptx
analog design.pptxanalog design.pptx
analog design.pptx
PurushothamKN1
 
anti hypertensive agents.pptx
anti hypertensive agents.pptxanti hypertensive agents.pptx
anti hypertensive agents.pptx
PurushothamKN1
 
Chemistry of Prostaglandins,Leukotrienes and Thromboxanes.pptx
Chemistry of Prostaglandins,Leukotrienes and Thromboxanes.pptxChemistry of Prostaglandins,Leukotrienes and Thromboxanes.pptx
Chemistry of Prostaglandins,Leukotrienes and Thromboxanes.pptx
PurushothamKN1
 
COX.pptx
COX.pptxCOX.pptx
COX.pptx
PurushothamKN1
 
drug discovery.pptx
drug discovery.pptxdrug discovery.pptx
drug discovery.pptx
PurushothamKN1
 
prinz metal angina.pptx
prinz metal angina.pptxprinz metal angina.pptx
prinz metal angina.pptx
PurushothamKN1
 
prodrug.pptx
prodrug.pptxprodrug.pptx
prodrug.pptx
PurushothamKN1
 
Rationale of prodrug design.pptx
Rationale of prodrug design.pptxRationale of prodrug design.pptx
Rationale of prodrug design.pptx
PurushothamKN1
 
REACTION PROGRESS KINETIC ANALYSIS.pptx
REACTION PROGRESS KINETIC ANALYSIS.pptxREACTION PROGRESS KINETIC ANALYSIS.pptx
REACTION PROGRESS KINETIC ANALYSIS.pptx
PurushothamKN1
 
REDUCTION.pptx
REDUCTION.pptxREDUCTION.pptx
REDUCTION.pptx
PurushothamKN1
 
INTRODUCTION TO PROCESS CHEMISTRY.pptx
INTRODUCTION TO PROCESS CHEMISTRY.pptxINTRODUCTION TO PROCESS CHEMISTRY.pptx
INTRODUCTION TO PROCESS CHEMISTRY.pptx
PurushothamKN1
 

More from PurushothamKN1 (20)

Chemistry of Prostaglandins,Leukotrienes and Thromboxanes.pptx
Chemistry of Prostaglandins,Leukotrienes and Thromboxanes.pptxChemistry of Prostaglandins,Leukotrienes and Thromboxanes.pptx
Chemistry of Prostaglandins,Leukotrienes and Thromboxanes.pptx
 
SAR of Quinolines.pptx
SAR of Quinolines.pptxSAR of Quinolines.pptx
SAR of Quinolines.pptx
 
OECD GUIDELINES.pptx
OECD GUIDELINES.pptxOECD GUIDELINES.pptx
OECD GUIDELINES.pptx
 
modify of peptidomimetics.pptx
modify of peptidomimetics.pptxmodify of peptidomimetics.pptx
modify of peptidomimetics.pptx
 
INDUSTRIAL SAFETY.pptx
INDUSTRIAL SAFETY.pptxINDUSTRIAL SAFETY.pptx
INDUSTRIAL SAFETY.pptx
 
01. Combating Drug Resistance.pptx
01. Combating Drug Resistance.pptx01. Combating Drug Resistance.pptx
01. Combating Drug Resistance.pptx
 
02.Anticonvulsant and H1 and H2 receptor antagonist.pptx
02.Anticonvulsant and H1 and H2 receptor antagonist.pptx02.Anticonvulsant and H1 and H2 receptor antagonist.pptx
02.Anticonvulsant and H1 and H2 receptor antagonist.pptx
 
02.High through output screening.pptx
02.High through output screening.pptx02.High through output screening.pptx
02.High through output screening.pptx
 
Adrenergic and cholinergic agents pptx.pptx
Adrenergic and cholinergic agents pptx.pptxAdrenergic and cholinergic agents pptx.pptx
Adrenergic and cholinergic agents pptx.pptx
 
analog design.pptx
analog design.pptxanalog design.pptx
analog design.pptx
 
anti hypertensive agents.pptx
anti hypertensive agents.pptxanti hypertensive agents.pptx
anti hypertensive agents.pptx
 
Chemistry of Prostaglandins,Leukotrienes and Thromboxanes.pptx
Chemistry of Prostaglandins,Leukotrienes and Thromboxanes.pptxChemistry of Prostaglandins,Leukotrienes and Thromboxanes.pptx
Chemistry of Prostaglandins,Leukotrienes and Thromboxanes.pptx
 
COX.pptx
COX.pptxCOX.pptx
COX.pptx
 
drug discovery.pptx
drug discovery.pptxdrug discovery.pptx
drug discovery.pptx
 
prinz metal angina.pptx
prinz metal angina.pptxprinz metal angina.pptx
prinz metal angina.pptx
 
prodrug.pptx
prodrug.pptxprodrug.pptx
prodrug.pptx
 
Rationale of prodrug design.pptx
Rationale of prodrug design.pptxRationale of prodrug design.pptx
Rationale of prodrug design.pptx
 
REACTION PROGRESS KINETIC ANALYSIS.pptx
REACTION PROGRESS KINETIC ANALYSIS.pptxREACTION PROGRESS KINETIC ANALYSIS.pptx
REACTION PROGRESS KINETIC ANALYSIS.pptx
 
REDUCTION.pptx
REDUCTION.pptxREDUCTION.pptx
REDUCTION.pptx
 
INTRODUCTION TO PROCESS CHEMISTRY.pptx
INTRODUCTION TO PROCESS CHEMISTRY.pptxINTRODUCTION TO PROCESS CHEMISTRY.pptx
INTRODUCTION TO PROCESS CHEMISTRY.pptx
 

Recently uploaded

How to Make a Field invisible in Odoo 17
How to Make a Field invisible in Odoo 17How to Make a Field invisible in Odoo 17
How to Make a Field invisible in Odoo 17
Celine George
 
Additional Benefits for Employee Website.pdf
Additional Benefits for Employee Website.pdfAdditional Benefits for Employee Website.pdf
Additional Benefits for Employee Website.pdf
joachimlavalley1
 
GIÁO ÁN DẠY THÊM (KẾ HOẠCH BÀI BUỔI 2) - TIẾNG ANH 8 GLOBAL SUCCESS (2 CỘT) N...
GIÁO ÁN DẠY THÊM (KẾ HOẠCH BÀI BUỔI 2) - TIẾNG ANH 8 GLOBAL SUCCESS (2 CỘT) N...GIÁO ÁN DẠY THÊM (KẾ HOẠCH BÀI BUỔI 2) - TIẾNG ANH 8 GLOBAL SUCCESS (2 CỘT) N...
GIÁO ÁN DẠY THÊM (KẾ HOẠCH BÀI BUỔI 2) - TIẾNG ANH 8 GLOBAL SUCCESS (2 CỘT) N...
Nguyen Thanh Tu Collection
 
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdf
Welcome to TechSoup   New Member Orientation and Q&A (May 2024).pdfWelcome to TechSoup   New Member Orientation and Q&A (May 2024).pdf
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdf
TechSoup
 
ESC Beyond Borders _From EU to You_ InfoPack general.pdf
ESC Beyond Borders _From EU to You_ InfoPack general.pdfESC Beyond Borders _From EU to You_ InfoPack general.pdf
ESC Beyond Borders _From EU to You_ InfoPack general.pdf
Fundacja Rozwoju Społeczeństwa Przedsiębiorczego
 
Polish students' mobility in the Czech Republic
Polish students' mobility in the Czech RepublicPolish students' mobility in the Czech Republic
Polish students' mobility in the Czech Republic
Anna Sz.
 
PART A. Introduction to Costumer Service
PART A. Introduction to Costumer ServicePART A. Introduction to Costumer Service
PART A. Introduction to Costumer Service
PedroFerreira53928
 
Model Attribute Check Company Auto Property
Model Attribute  Check Company Auto PropertyModel Attribute  Check Company Auto Property
Model Attribute Check Company Auto Property
Celine George
 
How to Break the cycle of negative Thoughts
How to Break the cycle of negative ThoughtsHow to Break the cycle of negative Thoughts
How to Break the cycle of negative Thoughts
Col Mukteshwar Prasad
 
Supporting (UKRI) OA monographs at Salford.pptx
Supporting (UKRI) OA monographs at Salford.pptxSupporting (UKRI) OA monographs at Salford.pptx
Supporting (UKRI) OA monographs at Salford.pptx
Jisc
 
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
siemaillard
 
special B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdfspecial B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdf
Special education needs
 
The Art Pastor's Guide to Sabbath | Steve Thomason
The Art Pastor's Guide to Sabbath | Steve ThomasonThe Art Pastor's Guide to Sabbath | Steve Thomason
The Art Pastor's Guide to Sabbath | Steve Thomason
Steve Thomason
 
The Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official PublicationThe Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official Publication
Delapenabediema
 
Instructions for Submissions thorugh G- Classroom.pptx
Instructions for Submissions thorugh G- Classroom.pptxInstructions for Submissions thorugh G- Classroom.pptx
Instructions for Submissions thorugh G- Classroom.pptx
Jheel Barad
 
Sha'Carri Richardson Presentation 202345
Sha'Carri Richardson Presentation 202345Sha'Carri Richardson Presentation 202345
Sha'Carri Richardson Presentation 202345
beazzy04
 
The approach at University of Liverpool.pptx
The approach at University of Liverpool.pptxThe approach at University of Liverpool.pptx
The approach at University of Liverpool.pptx
Jisc
 
Language Across the Curriculm LAC B.Ed.
Language Across the  Curriculm LAC B.Ed.Language Across the  Curriculm LAC B.Ed.
Language Across the Curriculm LAC B.Ed.
Atul Kumar Singh
 
Ethnobotany and Ethnopharmacology ......
Ethnobotany and Ethnopharmacology ......Ethnobotany and Ethnopharmacology ......
Ethnobotany and Ethnopharmacology ......
Ashokrao Mane college of Pharmacy Peth-Vadgaon
 
Fish and Chips - have they had their chips
Fish and Chips - have they had their chipsFish and Chips - have they had their chips
Fish and Chips - have they had their chips
GeoBlogs
 

Recently uploaded (20)

How to Make a Field invisible in Odoo 17
How to Make a Field invisible in Odoo 17How to Make a Field invisible in Odoo 17
How to Make a Field invisible in Odoo 17
 
Additional Benefits for Employee Website.pdf
Additional Benefits for Employee Website.pdfAdditional Benefits for Employee Website.pdf
Additional Benefits for Employee Website.pdf
 
GIÁO ÁN DẠY THÊM (KẾ HOẠCH BÀI BUỔI 2) - TIẾNG ANH 8 GLOBAL SUCCESS (2 CỘT) N...
GIÁO ÁN DẠY THÊM (KẾ HOẠCH BÀI BUỔI 2) - TIẾNG ANH 8 GLOBAL SUCCESS (2 CỘT) N...GIÁO ÁN DẠY THÊM (KẾ HOẠCH BÀI BUỔI 2) - TIẾNG ANH 8 GLOBAL SUCCESS (2 CỘT) N...
GIÁO ÁN DẠY THÊM (KẾ HOẠCH BÀI BUỔI 2) - TIẾNG ANH 8 GLOBAL SUCCESS (2 CỘT) N...
 
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdf
Welcome to TechSoup   New Member Orientation and Q&A (May 2024).pdfWelcome to TechSoup   New Member Orientation and Q&A (May 2024).pdf
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdf
 
ESC Beyond Borders _From EU to You_ InfoPack general.pdf
ESC Beyond Borders _From EU to You_ InfoPack general.pdfESC Beyond Borders _From EU to You_ InfoPack general.pdf
ESC Beyond Borders _From EU to You_ InfoPack general.pdf
 
Polish students' mobility in the Czech Republic
Polish students' mobility in the Czech RepublicPolish students' mobility in the Czech Republic
Polish students' mobility in the Czech Republic
 
PART A. Introduction to Costumer Service
PART A. Introduction to Costumer ServicePART A. Introduction to Costumer Service
PART A. Introduction to Costumer Service
 
Model Attribute Check Company Auto Property
Model Attribute  Check Company Auto PropertyModel Attribute  Check Company Auto Property
Model Attribute Check Company Auto Property
 
How to Break the cycle of negative Thoughts
How to Break the cycle of negative ThoughtsHow to Break the cycle of negative Thoughts
How to Break the cycle of negative Thoughts
 
Supporting (UKRI) OA monographs at Salford.pptx
Supporting (UKRI) OA monographs at Salford.pptxSupporting (UKRI) OA monographs at Salford.pptx
Supporting (UKRI) OA monographs at Salford.pptx
 
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
 
special B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdfspecial B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdf
 
The Art Pastor's Guide to Sabbath | Steve Thomason
The Art Pastor's Guide to Sabbath | Steve ThomasonThe Art Pastor's Guide to Sabbath | Steve Thomason
The Art Pastor's Guide to Sabbath | Steve Thomason
 
The Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official PublicationThe Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official Publication
 
Instructions for Submissions thorugh G- Classroom.pptx
Instructions for Submissions thorugh G- Classroom.pptxInstructions for Submissions thorugh G- Classroom.pptx
Instructions for Submissions thorugh G- Classroom.pptx
 
Sha'Carri Richardson Presentation 202345
Sha'Carri Richardson Presentation 202345Sha'Carri Richardson Presentation 202345
Sha'Carri Richardson Presentation 202345
 
The approach at University of Liverpool.pptx
The approach at University of Liverpool.pptxThe approach at University of Liverpool.pptx
The approach at University of Liverpool.pptx
 
Language Across the Curriculm LAC B.Ed.
Language Across the  Curriculm LAC B.Ed.Language Across the  Curriculm LAC B.Ed.
Language Across the Curriculm LAC B.Ed.
 
Ethnobotany and Ethnopharmacology ......
Ethnobotany and Ethnopharmacology ......Ethnobotany and Ethnopharmacology ......
Ethnobotany and Ethnopharmacology ......
 
Fish and Chips - have they had their chips
Fish and Chips - have they had their chipsFish and Chips - have they had their chips
Fish and Chips - have they had their chips
 

STEREOCHEMISTRY.pptx

  • 1. Presenting by: MR. PURUSHOTHAM K N Asst. Professor Department of Pharmaceutical Chemistry SACCP,B.G.Nagara 2021-2022 Stereochemistry and Drug Action
  • 2. • Stereochemistry mainly deals with the spatial arrangements of the atoms or group of atoms in a molecules.
  • 3. • A clear understanding of stereochemistry is crucial for the study of complex molecules that are biologically important e.g. Protiens, carbohydrates, nucleic acids and drug molecules (especially in relation to their behavior and pharmacological actions).
  • 4. IMPORTANT DEFINITIONS • Isomerism refers to the phenomenon in which more than one compounds have the same chemical formula but different chemical structures. And those chemical compounds that have identical chemical formulae but they differ in physical or chemical properties and the arrangement of atoms in the molecule are called isomers. Therefore, the compounds that possess isomerism are called “isomers”.
  • 5. • Chirality is defined as an object or a compound which is asymmetric and cannot be superimposed over its mirror image (for example, our both palms) is known as ‘chiral’ or ‘stereocenter’ and this property is known as “chirality”. The chirality is due to the three-dimensional or spatial arrangements of the molecules and a carbon is said to be chiral carbon when it is bonded with four different substituents to it. The asymmetry of the molecule or chirality is mainly responsible for the optical activity in such organic compounds.
  • 6. • Example: Asymmetric or chiral compounds •A carbon within an organic compound that contains four different atoms or group of atoms (substituents) bonded to it. •A carbon with double and triple bond cannot be considered as asymmetric because it contain 2 and 3 total bonds respectively.
  • 7.
  • 8.
  • 9. • STEREOISOMERS: Isomers that have same molecular formula and connectivity but differ in a way that atoms are oriented in space – i.e; Difference between isomers lies only in 3D arrangements of atoms.
  • 10. • ENANTIOMER: Greek word: enantio : opposite merons : parts Stereoisomers with non superimposable mirror images. • DIASTEREOMER : Diastereomers are stereoisomers that are not mirror images of one another and are non-superimposable on one another. Stereoisomers with two or more stereocenters can be diastereomers.
  • 11.
  • 12. Stereoisomers Configurational isomer : • Geometric isomers : (a) cis & trans system / E & Z system • Relative configuration / Fischer projection ( L & D configuration) • Absolute configuration (R & S configuration
  • 13. CIS AND TRANS CONFIGURATION
  • 14. L AND D CONFIGURATION
  • 15. R and S CONFIGURATION • Priority of an atom is determined by its atomic number • Order of substituents going from highest to lowest priority. • Clockwise – R (rectus). • Anticlockwise – S (sinister). • Unless established experimentally no idea whether (+) or (-) rotation is associated with R or S configuration
  • 16. Importance of the chirality in drugs • This stereoisomerism results in different physical and chemical properties of the compound. If this compound happens to be drug then it results in different pharmacokinetic and pharmaco dynamic properties • The importance of chiral drugs in the drug development space cannot be understated. In pharmaceutical industries, 56% of the drugs currently in use are chiral molecules and 88% of the last ones are marketed as racemates (or racemic mixtures), consisting of an equimolar mixture of two enantiomers
  • 17. Thalidomide-disastrous • biological activity of the wrong enantiomer • In 1960 in Europe, racemic thalidomide was given to pregnant females to cure morning sickness. • This led to deformations in babies and neurotoxic effects. • These were due to S- thalidomide. • R-thalidomide contained the desired therapeutic activity
  • 18.
  • 19. EXAMPLES OF CHIRAL DRUGS • INTRAVENOUS ANAESTHETICS • LOCAL ANAESTHETICS • INHALATIONAL AGENTS • NUEROMUSCULAR BLOCKING AGENTS • SOME OTHER DRUGS
  • 20. Intravenous anaesthetics Etomidate • Administered as a single isomer: R-isomer. • Site of action: GABAA receptor. • R-isomer is 15 times more potent than the S-isomer. • S-isomer lacks hypnotic activity.
  • 21. LOCAL ANAESTEHTICS BUPIVACAINE • Long acting local anaesthetic marketed as 50:50 racemic mixture. Reports of death due to • Bupivacaine induced CNS toxicity and cardiotoxicity on accidental intravenous injection and difficult resuscitation following cardiotoxicity. Safer alternatives • Levobupivacaine • Ropivacaine These are S- enantiomers of bupivacaine. • Ropivacaine is the first ‘pure’ enantiomer containing >99% of the S-form
  • 22. • Potential advantages of single enantiomer products: • Less complex, more selective pharmacodynamic profile • Potential for an improved therapeutic index • Less complex pharmacokinetic profile Reduced potential for complex drug interactions • Less complex relationship between plasma concentration and effect
  • 24. Pharmacokinetics stereoselectivity Absorption • Passive intestinal absorption • Carrier transporter stereoselectivity Distribution • Protein binding • Tissue distribution Metabolism • first pass metabolism • Phase I and phase II metabolism Elimination
  • 25. Absorption and stereoselectivity • Passive intestinal absorption For the majority of racemic drugs, absorption appears to be by passive diffusion , provided no stereoselectivity
  • 26. Carrier mediated transporter • Stereo selective intestinal transporter is the main cause for marked differences in the oral absorption of enantiomers. L- Methotrexate have 40 fold higher Cmax and AUC than D- Methotrexate
  • 27. Distribution Protein binding • Stereo selective plasma protein binding could influence distribution and elimination because the major determinant of drug distribution and elimination is protein binding. • The enantiomers may display different magnitudes of stereoselectivity between the various proteins found in plasma • Ex// the R- propranolol binding to albumin is greater than S- propranolol and the opposite is observed for 1 -acid glycoprotein.
  • 28. R- propranolol • Highly albumin bound • Less potent S- propranolol • highly bound to AAG available as unbound • 40-100 time more potent
  • 29. • Metabolism first pass metabolism Stereo selective drug metabolism is commonly observed in vitro for racemic drugs and can results in substantial differences in the vivo plasma concentration - time profiles between enantiomers due to stereo selective bioavailability or drug disposition. • some time the two isomers compete with each other to bind the enzyme binding site, this result in inhibition the metabolism of the one enantiomer. Ex// propaphenone
  • 30.
  • 31.